Evidence map›Paper›PMID 42319369›Full record

Trial reportJournal of comparative effectiveness research2026

Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison.

Handrean Soran, Asia Sikora Kessler, Montserrat Vera-Llonch, Veronica J Alexander, Paul Serafini, Divya Pushkarna, Elisabete Rodrigues, Erik Stroes, Ulrike Schatz, Ursula Kassner and 3 more

Abstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of comparative effectiveness research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Handrean SoranNIHR/Welcome Trust Clinical Research Facility & Manchester University Hospital NHS Foundation Trust, Manchester, UK.
Asia Sikora KesslerIonis Pharmaceuticals Inc., Carlsbad, CA, USA.ORCID 0000-0001-9417-6637
Montserrat Vera-LlonchIonis Pharmaceuticals Inc., Carlsbad, CA, USA.ORCID 0009-0007-0669-1657
Veronica J AlexanderIonis Pharmaceuticals Inc., Carlsbad, CA, USA.ORCID 0000-0003-3729-5749
Paul SerafiniEvidinno Outcomes Research Inc., Vancouver, BC, Canada.ORCID 0009-0007-9773-5837
Divya PushkarnaEvidinno Outcomes Research Inc., Vancouver, BC, Canada.ORCID 0000-0002-6680-4074
Elisabete RodriguesDepartment of Endocrinology, ULS Sao Joao, Faculty of Medicine, University of Porto (FMUP), Porto, Portugal.
Erik StroesDepartment of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands.ORCID 0009-0000-7584-7677
Ulrike SchatzDepartment of Internal Medicine III of the University Hospital Dresden, Technical University of Dresden, Germany.ORCID 0000-0001-8009-9482
Ursula KassnerDepartment of Endocrinology, Division of Lipid Disorders, Berlin, Germany.ORCID 0000-0002-4536-7063
Zalmai HakimiSobi, Stockholm, Sweden.ORCID 0000-0001-5835-8599
Aletta FalkSobi, Stockholm, Sweden.
Koo WilsonSobi, Stockholm, Sweden.ORCID 0000-0002-8732-8249

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hyperlipoproteinemia Type IHyperlipoproteinemia Type IIOligonucleotidesAdultApolipoprotein C-IIIFemaleHumansMaleMiddle AgedPancreatitisTreatment OutcomeTriglyceridesApolipoprotein C-IIIISIS 304801olezarsenOligonucleotidesTriglyceridesfamilial chylomicronemia syndromehypertriglyceridemiaindirect treatment comparisonolezarsenvolanesorsen

Identifiers

PMID42319369
PMCPMC13329855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.